title: Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer.
abstract: Long-standing inflammation has emerged as a hallmark of neoplastic transformation of epithelial cells and may be a limiting factor of successful conventional tumor therapies. A complex milieu composed of distinct stromal and immune cells, soluble factors and inflammatory mediators plays a crucial role in supporting and promoting various types of cancers. An augmented inflammatory response can predispose a patient to colorectal cancer (CRC). Common risk factors associated with CRC development include diet and lifestyle, altered intestinal microbiota and commensals, and chronic inflammatory bowel diseases. Cysteinyl leukotrienes are potent inflammatory metabolites synthesized from arachidonic acid and have a broad range of functions involved in the etiology of various pathologies. This review discusses the important role of cysteinyl leukotriene signaling in linking inflammation and CRC.
authors.affiliation: Sayeh Savari, Katyayni Vinnakota, Yuan Zhang, Anita Sjölander, Division of Cell and Experimental Pathology, Department of Laboratory Medicine, Lund University, Skåne University Hospital, SE-205 02 Malmö, Sweden.
authors.forename: Sayeh
authors.initials: S
authors.lastname: Savari
authors.affiliation: Sayeh Savari, Katyayni Vinnakota, Yuan Zhang, Anita Sjölander, Division of Cell and Experimental Pathology, Department of Laboratory Medicine, Lund University, Skåne University Hospital, SE-205 02 Malmö, Sweden.
authors.forename: Katyayni
authors.initials: K
authors.lastname: Vinnakota
authors.affiliation: Sayeh Savari, Katyayni Vinnakota, Yuan Zhang, Anita Sjölander, Division of Cell and Experimental Pathology, Department of Laboratory Medicine, Lund University, Skåne University Hospital, SE-205 02 Malmö, Sweden.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Sayeh Savari, Katyayni Vinnakota, Yuan Zhang, Anita Sjölander, Division of Cell and Experimental Pathology, Department of Laboratory Medicine, Lund University, Skåne University Hospital, SE-205 02 Malmö, Sweden.
authors.forename: Anita
authors.initials: A
authors.lastname: Sjölander
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002471:Cell Transformation, Neoplastic / Q000276:immunology / Q000378:metabolism; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism*; D003545:Cysteine / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004751:Enteritis / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism*; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000378:metabolism*; D007420:Intestine, Large / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D015289:Leukotrienes / Q000378:metabolism*; D011379:Prognosis; D018077:Receptors, Leukotriene / Q000187:drug effects / Q000378:metabolism*; D012307:Risk Factors; D015398:Signal Transduction
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018836:Inflammation Mediators; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D018077:Receptors, Leukotriene; C112381:cysteinyl-leukotriene; D003545:Cysteine; C083169:leukotriene D4 receptor
keywords: Colorectal cancer; CysLT1R; CysLT2R; Cysteinyl leukotrienes; Eicosanoids; Inflammation